GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (FRA:R3I1) » Definitions » EV-to-FCF

Advanced Oncotherapy (FRA:R3I1) EV-to-FCF : -1.76 (As of Jun. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Advanced Oncotherapy EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Advanced Oncotherapy's Enterprise Value is €78.70 Mil. Advanced Oncotherapy's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 was €-44.76 Mil. Therefore, Advanced Oncotherapy's EV-to-FCF for today is -1.76.

The historical rank and industry rank for Advanced Oncotherapy's EV-to-FCF or its related term are showing as below:

FRA:R3I1's EV-to-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 27.515
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Advanced Oncotherapy's stock price is €0.0215. Advanced Oncotherapy's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was €-0.083. Therefore, Advanced Oncotherapy's PE Ratio for today is At Loss.


Advanced Oncotherapy EV-to-FCF Historical Data

The historical data trend for Advanced Oncotherapy's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy EV-to-FCF Chart

Advanced Oncotherapy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.07 -5.01 -4.00 -6.10 -5.69

Advanced Oncotherapy Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -6.10 - -5.69 -

Competitive Comparison of Advanced Oncotherapy's EV-to-FCF

For the Medical Devices subindustry, Advanced Oncotherapy's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Oncotherapy's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Oncotherapy's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Advanced Oncotherapy's EV-to-FCF falls into.



Advanced Oncotherapy EV-to-FCF Calculation

Advanced Oncotherapy's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=78.701/-44.755
=-1.76

Advanced Oncotherapy's current Enterprise Value is €78.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advanced Oncotherapy's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 was €-44.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Oncotherapy  (FRA:R3I1) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Advanced Oncotherapy's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0215/-0.083
=At Loss

Advanced Oncotherapy's share price for today is €0.0215.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advanced Oncotherapy's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was €-0.083.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Advanced Oncotherapy EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Oncotherapy (FRA:R3I1) Business Description

Traded in Other Exchanges
N/A
Address
4 Tenterden Street, Third Floor, London, GBR, W1S 1TE
Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.

Advanced Oncotherapy (FRA:R3I1) Headlines

No Headlines